Loading clinical trials...

A Study on the Verification of Kidney CT Non-inferiority Using Low Concentration Contrast Agent | Clinical Trials | Clareo Health

UNKNOWN

A Study on the Verification of Kidney CT Non-inferiority Using Low Concentration Contrast Agent

Low Tube Voltage Kidney Computed Tomography Using Low Concentration Iodine Contrast Agent: A Comparison Study With Conventional CT Protocol

NCT05831943•Seoul National University Hospital

View on ClinicalTrials.gov

Summary

This prospective study aims to evaluate clinical usefulness of low-voltage renal CT using low-concentration contrast agent and to compare with existing imaging techniques.

Eligibility

Age

19 - 80 years

Sex

ALL

Healthy Volunteers

Yes

Inclusion Criteria

•Subjects with no abnormalities in renal function (Serum creatinine \< 1.4 mg/dl , GFR \> 45mL/min/1.73 m2) in blood tests performed within one month
•Those who understand the contents of the research subject explanation and voluntarily sign the consent form

Exclusion Criteria

•Body mass index \> 30
•Subjects whose renal function abnormality was confirmed in a blood test (Serum creatinine \> 1.4 mg/dl , GFR \< 45mL/min/1.73 m2) conducted within one month
•Diabetic patients taking metformin
•Those with a history of urinary tract obstruction
•Those with a history of bladder, urinary tract, or kidney surgery that may affect the evaluation of the contrast agent in the renal parenchyma
•Those whose anatomical deformities have been identified in previous images that may interfere with image analysis
•Those who know or have been reported to have a history of contrast agent side effects in previous CT scans
•Those with a history of hypersensitivity or adverse reactions to iobrix (intravascular CT contrast) or iodine based agent
•Those with severe thyroid disease
•Pregnancy
+1 more criteria

Locations (1)

Seoul National University Hospital

Seoul, Jong-no Gu, South Korea

Key Dates

Start Date

January 20, 2023

Primary Completion Date

June 30, 2023

Completion Date

August 30, 2023

Last Updated

April 26, 2023

Enrollment

ESTIMATED participants

Conditions

Renal Disease

Interventions

Contrast enhanced Kidney CT

DIAGNOSTIC_TEST

Contacts

June Young Seo, MD

CONTACT

82-2-2072-2518 razorwind4@naver.com

Post-market Surveillance Study of the BD® WavelinQ™ EndoAVF System

NCT04634916

Kidney Disease, End-StageEnd-stage Renal Disease+1 more

View study

RECRUITINGPHASE3

A Study of a Novel Iron-based Phosphate Binder AP301 in Patients With Hyperphosphatemia in the U.S. and China

NCT06933472

HyperphosphatemiaChronic Kidney Disease, Receiving Dialysis+2 more

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: April 26, 2023Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

A Study on the Verification of Kidney CT Non-inferiority Using Low Concentration Contrast Agent

Inclusion Criteria

Exclusion Criteria

Post-market Surveillance Study of the BD® WavelinQ™ EndoAVF System

A Study of a Novel Iron-based Phosphate Binder AP301 in Patients With Hyperphosphatemia in the U.S. and China

EndoForce Post Approval Study

Blood Pressure Slopes and Ultrafiltration in Hemodialysis Patients

Safety & Efficacy of DCR-PHXC in Patients With PH1 and ESRD

Study to Evaluate the Safety and Efficacy of the GGTA1 KO Thymokidney in Patients With ESRD